Sponsor: ClearView Healthcare Partners

Delivering new and innovative products to market is critical to growth and success in the biopharmaceutical industry. However, as companies face the need to discover or acquire future drivers of value, R&D is both challenging and costly, with over $150 B spent globally in 2016 alone. In this session, we will examine how market forces and overall value in therapeutic areas, ranging from oncology to rare disease, may drive investment decisions in R&D and M&A both today and into the future. We will highlight emerging clusters of innovation within the biopharmaceutical industry, including key therapeutic targets and novel mechanistic approaches, dissecting how those align with current commercial value to identify potential areas of value creation in the future.

Join us for a forward-looking discussion of what’s next for R&D in the global pharmaceutical industry, highlighting noteworthy differences in disease areas of focus and therapeutic targets relevant for companies of all sizes. We will share perspectives on geographic considerations including regions serving as hotbeds of innovative activity and seek to identify the drivers that will shape future areas of value within the pharmaceutical industry.

Session ID: 228187